Synopsis

Epilepsy the most common, serious chronic neurological disease worldwide, affecting 50 million people globally. Current treatment with anti-seizure drugs (ASD) is symptomatic, suppressing seizures, while the medication is being taken at appropriate doses, but having sustained effects, and no effects on the accompanying comorbidities. More than a third of patients with PTE do not have their seizures controlled with currently available ASDs. In-vivo neuroimaging, in particular MRI, is a highly valuable tool in the pre-clinical testing of potential disease modifying treatments for epilepsy, allowing serial assessments of brain structure and function to evaluate the long-term effects of the treatment.